Niglys (glyceryl trinitrate): Uses, Dosage & Side Effects

What it's for (Indications)

Glyceryl trinitrate, commonly known as nitroglycerin, is primarily indicated for the acute relief of an attack or acute prophylaxis of angina pectoris, a condition characterized by chest pain due to myocardial ischemia.
It is also prescribed for the prevention of situational angina, where patients can administer the medication proactively before engaging in activities known to precipitate their angina symptoms, such as physical exertion or emotional stress.
Furthermore, intravenous formulations of glyceryl trinitrate are utilized as an adjunct in the treatment of acute myocardial infarction (heart attack) to reduce cardiac workload and improve coronary perfusion, and in the management of acute congestive heart failure, particularly when associated with myocardial ischemia or hypertension, by reducing both preload and afterload.
Its diverse delivery methods, including sublingual, transdermal, and intravenous, allow for tailored therapeutic approaches depending on the urgency and nature of the patient's cardiac condition.

Dosage Information

Type	Guideline
Standard	The dosage of glyceryl trinitrate varies significantly depending on the formulation and the clinical indication. For acute angina relief, sublingual tablets or sprays are typically administered at 0.3 mg, 0.4 mg, or 0.6 mg, with 0.4 mg being a common initial dose. Patients are usually instructed to take one dose at the onset of angina and may repeat the dose every 5 minutes for a maximum of three doses within a 15-minute period. If pain persists after three doses, emergency medical attention should be sought immediately. For the prophylactic management of angina with transdermal patches, doses generally range from 0.2 mg/hr to 0.8 mg/hr, applied once daily, crucially incorporating a daily nitrate-free interval of 10-14 hours to prevent the development of nitrate tolerance. Intravenous glyceryl trinitrate is administered as a continuous infusion, with the dosage precisely titrated based on the patient's clinical response, blood pressure, and relief of symptoms, often starting at low rates (e.g., 5 mcg/min) and gradually increasing. Oral extended-release formulations are also available for chronic prophylaxis, typically taken once or twice daily, but are not suitable for acute symptom relief.

Type

Guideline

Standard

The dosage of glyceryl trinitrate varies significantly depending on the formulation and the clinical indication. For acute angina relief, sublingual tablets or sprays are typically administered at 0.3 mg, 0.4 mg, or 0.6 mg, with 0.4 mg being a common initial dose. Patients are usually instructed to take one dose at the onset of angina and may repeat the dose every 5 minutes for a maximum of three doses within a 15-minute period. If pain persists after three doses, emergency medical attention should be sought immediately. For the prophylactic management of angina with transdermal patches, doses generally range from 0.2 mg/hr to 0.8 mg/hr, applied once daily, crucially incorporating a daily nitrate-free interval of 10-14 hours to prevent the development of nitrate tolerance. Intravenous glyceryl trinitrate is administered as a continuous infusion, with the dosage precisely titrated based on the patient's clinical response, blood pressure, and relief of symptoms, often starting at low rates (e.g., 5 mcg/min) and gradually increasing. Oral extended-release formulations are also available for chronic prophylaxis, typically taken once or twice daily, but are not suitable for acute symptom relief.

Safety & Warnings

Common Side Effects

Glyceryl trinitrate, while highly effective, is associated with a range of side effects primarily related to its potent vasodilatory properties.
The most frequently reported adverse effect is headache, often described as throbbing, which can be severe and is commonly referred to as 'nitrate-induced headache.
' Other common side effects include dizziness, lightheadedness, facial flushing, and a sensation of warmth.
Orthostatic hypotension, characterized by a significant drop in blood pressure upon standing, leading to presyncope or syncope, is a notable concern, especially in susceptible individuals or with higher doses.
Nausea and vomiting may also occur.
Less common but more serious adverse effects include severe and prolonged hypotension, reflex tachycardia (an increase in heart rate in response to falling blood pressure), and, rarely, methemoglobinemia, particularly with excessive doses or in patients with predisposing conditions.
Dermatitis may develop with transdermal patch use.
Patients should be advised to sit or lie down immediately if they experience dizziness or faintness after administration.

Serious Warnings

Black Box Warning: Glyceryl trinitrate does not carry a specific FDA-mandated 'Black Box Warning' in the style reserved for drugs with exceptionally serious safety concerns. However, given its profound hemodynamic effects and critical drug interactions, a prominent 'Serious Warnings' section is warranted to highlight the most significant safety considerations. The most critical interaction concerns the co-administration of glyceryl trinitrate with phosphodiesterase-5 (PDE5) inhibitors, including sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). This combination is absolutely contraindicated due to the potential for severe, prolonged, and life-threatening hypotension, which can lead to cardiovascular collapse, myocardial infarction, stroke, or even death. Patients must be explicitly informed about this interaction, and inquiry regarding PDE5 inhibitor use should be a routine part of assessment before prescribing or administering glyceryl trinitrate. Furthermore, clinicians must be vigilant for severe hypotension that may occur with any formulation of glyceryl trinitrate, particularly in patients who are volume-depleted, receiving other vasodilators, or have pre-existing low blood pressure. Patients should be educated on the signs of severe hypotension, such as dizziness, lightheadedness, or fainting, and instructed to seek immediate medical attention if these symptoms develop.
Glyceryl trinitrate necessitates careful administration due to several important warnings.
Profound hypotension can occur, particularly in patients who are volume-depleted, receiving concomitant diuretic therapy, or concurrently using other vasodilators.
Patients should be advised to remain seated or lie down for several minutes after sublingual administration to mitigate the risk of orthostatic hypotension and syncope.
There is a risk of reflex tachycardia as the body attempts to compensate for the sudden drop in blood pressure.
Glyceryl trinitrate should be used with extreme caution in patients with conditions that predispose them to increased intracranial pressure, such as recent head trauma or cerebral hemorrhage, as it can exacerbate these conditions.
Continuous use of long-acting formulations without a daily nitrate-free interval can lead to the development of nitrate tolerance, diminishing therapeutic efficacy.
Abrupt withdrawal of long-acting nitrates can precipitate angina symptoms.
Patients with hypertrophic obstructive cardiomyopathy (HOCM) or severe aortic stenosis are at increased risk of exacerbating outflow obstruction and should use glyceryl trinitrate with extreme caution, as the reduction in preload can worsen their clinical state.

How it Works (Mechanism of Action)

Glyceryl trinitrate functions as a potent vasodilator, primarily through its metabolic conversion to nitric oxide (NO) within vascular smooth muscle cells. This biotransformation is enzyme-dependent, involving mitochondrial aldehyde dehydrogenase (mtALDH) among other enzymes. Once formed, nitric oxide activates guanylate cyclase, an enzyme crucial for the synthesis of cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP). Elevated intracellular levels of cGMP lead to the dephosphorylation of the myosin light chain in smooth muscle cells, resulting in their relaxation. This widespread smooth muscle relaxation primarily affects both venous and arterial beds, with a more pronounced effect on the venous circulation. Venodilation reduces venous return to the heart, thereby decreasing cardiac preload (the volume of blood returning to the heart) and subsequently lowering ventricular wall stress and myocardial oxygen demand. Arterial dilation, particularly in the coronary arteries, helps to reduce afterload (the resistance the heart must pump against) and can improve blood flow to ischemic areas of the myocardium, alleviating angina symptoms by restoring the balance between myocardial oxygen supply and demand.